iX Biopharma Ltd

iX Biopharma Ltd is a Singapore public-listed late-stage specialty pharmaceutical company with a keen focus on the development and commercialisation of innovative therapies that improve the quality of life for those suffering from pain and other health conditions.

Our Company operates a fully integrated business model, with its fully-licensed facilities in Melbourne, Australia. Our Company is able to undertake drug development and formulation, laboratory testing, manufacturing and the supply of its products to consumers.

Our Company has also developed a patented, fast-dissolving wafer formulation, WaferiX™; a multiple platform technology (matrix for drug carrier) that can deliver a vast number of drugs and other active ingredients approved by regulatory bodies. This administration allows faster delivery and reduction in loss of drugs due to hepatic and gastrointestinal metabolism, hence improving the bioavailability of the drugs.

Sublingual wafer administration offers the convenience of use over oral delivery, circumventing the drug breakdown in liver or gastrointestinal tract. The technology also provides rapid absorption, achieving maximum desirable therapeutic effect in a non-invasive manner, however avoiding potentially toxic spike in plasma concentration usually seen on painful intravenous administration.